Trials / Completed
CompletedNCT00673088
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.
Detailed description
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ropinirole Hydrochloride | Restless Leg Syndrome |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2004-02-01
- Completion
- 2004-02-01
- First posted
- 2008-05-07
- Last updated
- 2018-01-23
Source: ClinicalTrials.gov record NCT00673088. Inclusion in this directory is not an endorsement.